GINA NOVAK: Open Payments
NPI 1932249778 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,798 in 107 payments from 27 companies in 2025. Trend: 2023 $1,663 · 2024 $1,207 · 2025 $1,798
Food & beverage: $1,798
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $224 |
| ABBVIE INC. | 25 | $192 |
| Lilly USA, LLC | 9 | $192 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $162 |
| PFIZER INC. | 15 | $157 |
| Astellas Pharma US Inc | 3 | $101 |
| Dexcom, Inc. | 5 | $97 |
| Novo Nordisk Inc | 5 | $77 |
| Amgen Inc. | 4 | $73 |
| E.R. Squibb & Sons, L.L.C. | 3 | $62 |
Products named: VRAYLAR, Kerendia, MOUNJARO, ELIQUIS, BREZTRI, Veozah, Dexcom G6 Transmitter, AIRSUPRA.
Industry payments across MD — which companies pay providers there.
